Tirzepatide in South Africa: 2026 Guide

For two years the weight loss conversation in South Africa was effectively a conversation about one compound. Semaglutide, under the Ozempic name, was what people asked about, argued about and queued for. That has changed.

Tirzepatide is now registered in South Africa, and as of late 2025 it is approved here for weight management rather than diabetes alone. That makes it the first dual-agonist in the country with a formal obesity indication, and it changes the questions worth asking.

This guide covers what tirzepatide actually is, what the trial evidence shows, what the local access and cost picture looks like, and where research-grade product fits — honestly.

What Is Tirzepatide?

Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly. Where semaglutide activates a single receptor, tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor.

Both GLP-1 and GIP are incretin hormones, released by the gut after eating. GLP-1 slows gastric emptying, suppresses glucagon, enhances glucose-dependent insulin release and acts on appetite centres in the brain. GIP influences insulin secretion too, but it also has receptors in adipose tissue, which is thought to be part of why adding GIP activity changes the metabolic picture rather than simply doubling the GLP-1 effect.

The practical consequence is a compound that, in head-to-head and cross-trial comparison, produces larger average weight reduction than semaglutide.

What the Evidence Actually Shows

Tirzepatide has a substantial trial record, which is worth separating from the marketing.

SURMOUNT-1 was the pivotal obesity trial. Adults with obesity, or overweight with at least one weight-related condition and without diabetes, received weekly tirzepatide for 72 weeks. Participants on the 15mg dose lost an average of around 21% of body weight. At the time of publication that was the largest average reduction recorded in a pharmaceutical obesity trial.

SURPASS-2 compared tirzepatide directly against semaglutide in people with type 2 diabetes over 40 weeks. Tirzepatide was superior to semaglutide on the primary endpoint of HbA1c reduction, and produced greater weight reduction as well. This is the trial most often cited when people say tirzepatide "beats" Ozempic, and it is worth knowing that it was conducted in a diabetic population at a 1mg semaglutide dose, not the 2.4mg obesity dose.

For context, the STEP 1 trial of semaglutide at 2.4mg produced an average of roughly 15% body weight reduction over 68 weeks. Comparing across separate trials is imperfect, but the direction is consistent.

Side effects are predominantly gastrointestinal — nausea, diarrhoea, constipation, vomiting — and are most pronounced during dose escalation. As with semaglutide, the class carries a boxed warning relating to thyroid C-cell tumours observed in rodents, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

The South African Access Picture

This is where the local situation has genuinely shifted.

Aspen Pharmacare distributes Mounjaro in South Africa under licence from Eli Lilly. It launched here in December 2024 for type 2 diabetes. In October 2025 SAHPRA approved the chronic weight management indication, meaning Mounjaro can now be prescribed in South Africa as an adjunct to a reduced-calorie diet and increased physical activity for long-term weight control.

A few practical points follow from that:

• It is a Schedule 4 medicine. It requires a prescription from a registered practitioner. There is no legitimate over-the-counter route.
• Mounjaro is the only registered tirzepatide brand in South Africa. If something is sold locally as tirzepatide under any other brand name as a registered medicine, treat that claim sceptically.
• Reported pharmacy pricing sits roughly between R2 800 and R5 500 per month, depending on dose. Higher doses cost more, and dose escalates over the first months.
• Medical aid cover is limited. Obesity is not a Prescribed Minimum Benefit condition in South Africa, which means schemes are not obliged to fund treatment for it. We cover this in detail in our guide to medical aid and weight-loss injections.

Tirzepatide vs Semaglutide: Choosing Between Them

The honest summary is that tirzepatide produces more weight loss on average, and semaglutide has the longer real-world safety record. Neither is a reason to dismiss the other. People who have plateaued on semaglutide, or who are starting with a larger reduction as the goal, are the ones most often drawn to tirzepatide.

Retatrutide, a triple agonist adding glucagon receptor activity, has produced larger phase 2 numbers still, but it is at an earlier stage of clinical development and is not registered anywhere as a medicine.

Where Research-Grade Tirzepatide Fits

We should be direct about this, because it is the question we are actually asked.

Pharmaceutical Mounjaro and research-grade tirzepatide are not the same thing in any regulatory sense. Mounjaro is a registered medicine, manufactured to pharmaceutical standards, dispensed on prescription, with a package insert, batch traceability and an adverse event reporting system behind it. Research-grade tirzepatide is sold as a research compound. It is not approved for human use, it carries no therapeutic claims, and quality varies by supplier because no regulator is checking every batch.

The reason a research-grade market exists in South Africa is cost. A registered course can run several thousand rand a month, medical aid generally will not fund it for weight management, and a large number of people who would benefit simply cannot reach that number.

That is a real gap, and pretending otherwise helps nobody. But the distinction matters, and anyone weighing it up should understand what they are giving up in oversight. If you are managing a diagnosed medical condition, the prescription route through a healthcare provider is the appropriate one.

What we can be held to is our end: independent third-party purity testing, a Certificate of Analysis available on request for anything we supply, and honest answers about the limits of the evidence.

Questions Worth Asking Before You Start

Whichever route you take:

• Have you had baseline bloodwork? HbA1c, fasting glucose, lipids, liver and kidney function and thyroid are the minimum worth knowing before a GLP-1 class compound.
• Do you understand the dose escalation schedule, and that side effects are worst during it?
• Do you know what happens when you stop? The trial data is clear that weight returns without sustained lifestyle change.
• Are you eating enough protein and doing resistance training? Rapid weight loss without both costs you lean mass.
• Are you in a risk category — personal or family history of medullary thyroid carcinoma, MEN 2, or pancreatitis — that makes this class inappropriate?

The Bottom Line

Tirzepatide is the most effective weight loss compound currently registered in South Africa, and since October 2025 it can be prescribed here specifically for weight management. The evidence behind it is strong and recent.

Cost remains the practical barrier for most South Africans, and that barrier is why the research-grade market exists. Understanding the difference between the two routes, and being honest with yourself about which one your situation calls for, is the part that actually matters.

Sources

The research, regulatory documents and clinical guidelines behind the claims in this article:

• Jastreboff AM, Aronne LJ, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
• Frias JP, Davies MJ, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021.
• Wilding JPH, Batterham RL, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 2018.
• Jastreboff AM, Kaplan LM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
• US Food and Drug Administration. WEGOVY (semaglutide) prescribing information, including the boxed warning on thyroid C-cell tumours. FDA label, 2021.
• Aspen Pharmacare. Aspen announces local availability of Lilly's Mounjaro in South Africa. Aspen Pharmacare, 2024.
• Aspen Pharmacare. Aspen secures SAHPRA approval for Mounjaro as a chronic weight management treatment (SENS announcement). Aspen Pharmacare, 2025.
• South African Health Products Regulatory Authority. Frequently asked questions: semaglutide, including what is and is not registered in South Africa. SAHPRA.
• Council for Medical Schemes. Prescribed Minimum Benefits, including the 26-condition Chronic Disease List. Council for Medical Schemes.

Disclaimer: The information in this article is for educational purposes only. STRIATA peptides are research compounds and are not approved medicines. Mounjaro is a registered Schedule 4 medicine available on prescription. Always consult a qualified healthcare professional before beginning any protocol.